YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Guardant360 CDx can now help identify cancer mutations earlier and drive improved patient outcomes in major global geographies This latest approval marks Guardant's 31st CDx approval PALO ALTO, Calif., October 08, 2026--(BUSINESS WIRE)--Gu…
AstraZeneca PLC (US) (NYSE:AZN) is on the cusp of unlocking a new growth engine in lung cancer treatment. On September 29, Reuters reported that the company has applied to the US Food and Drug Administration for approval of ORPATHYS-TAGRIS…
Pfizer PFE is a major global player in oncology, with a diversified presence across breast, genitourinary, thoracic, gastrointestinal and hematologic cancers. Its established portfolio of marketed cancer treatments is complemented by a rob…
Myriad Genetics, Inc. SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) today announce a c…
BOSTON, Oct. 8, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support pr…
Eli Lilly LLY is expected to deliver another quarter of robust growth from its oncology portfolio when it reports third-quarter results on Oct. 29. The franchise generated $4.84 billion in revenues in the first half of 2026, up 11% year ov…
AstraZeneca has been busy on the deal and research front, yet the more pressing question for you today is whether the current share price can be explained by the company's earnings power. Over the past 5 years the stock has gained 49.2%, w…
Veraxa is shifting away from animal testing to get drugs to market faster, calling it ‘not just a regulatory obligation, but a scientific opportunity.’ Continue Reading
Ironwood Pharmaceuticals' IRWD sole marketed product, Linzess (linaclotide), is witnessing strong prescription demand and uptake in recent times. The company has a partnership with drug giant AbbVie ABBV to jointly develop and commercializ…
Veraxa is shifting away from animal testing to get drugs to market faster, calling it ‘not just a regulatory obligation, but a scientific opportunity.’ Continue Reading
Global leaders share how they are applying decision intelligence to the decisions that run the business MOUNTAIN VIEW, Calif., October 07, 2026--(BUSINESS WIRE)--Aera Technology, the decision intelligence leader, today announced AeraHUB 26…
Bringing together scientific and technical expertise to advance development of hardware and software aimed at enabling a new wave of AI-driven, autonomous biologics discovery SALT LAKE CITY, October 07, 2026--(BUSINESS WIRE)--Carterra®, a…
AstraZeneca (LSE:AZN) has opened a new US$1b global R&D center in Kendall Square, Massachusetts, focused on multiple disease areas. The facility brings together work in oncology, cell therapy, chronic and rare diseases, and obesity under o…
In the latest trading session, Astrazeneca (AZN) closed at $158.61, marking a +1.33% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.58%. On the other hand, the Dow registered a gain of 0.…
Series B funding will strengthen Multiply Labs' momentum scaling the robotic manufacturing platform turning AI-discovered drugs into treatments patients can receive. SAN FRANCISCO, October 06, 2026--(BUSINESS WIRE)--Multiply Labs, the phys…
Merck's MRK stock has declined 7.2% in a month. Investors are looking at this correction as a pullback after a strong run rather than a deterioration in its core business. The stock has surged roughly 60% over the past year. It also reache…
RQ Bio Gavin KohChief Medical Officer of RQ Bio Dr Koh brings extensive infectious disease and clinical development expertise as RQ Bio prepares to advance RQB01 into the clinic Senior appointments across CMC, clinical operations and progr…
AstraZeneca's Kendall Square Global R&D Center photo credit: Aram Boghosian $1 billion investment will grow AstraZeneca's workforce in Massachusetts by over 50% and deliver next-generation medicines WILMINGTON, Del., October 05, 2026--(BUS…
The SERD market is expected to grow significantly due to factors like improved diagnosis, treatment advancements, demographics, increased awareness, and supportive regulations in the 7MM. Additionally, the recent approvals of SERD drugs su…
Summit Therapeutics SMMT is expanding the development of its sole investigational drug, ivonescimab, through a new clinical collaboration with AstraZeneca AZN and its Japan-based partner Daiichi Sankyo. Under the agreement, ivonescimab wil…
Eli Lilly LLY announced that the FDA has expanded the label of its oral cancer drug Jaypirca (pirtobrutinib) to include a new indication in chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Jaypirca has been approved to…
MIAMI, October 05, 2026--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca's (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support continu…
[Wall street sign in New York with New York Stock Exchange background] naphtalina/iStock via Getty Images Wall Street ended the week on a mixed note as cooler-than-expected September jobs data cut Fed rate-hike odds even as Treasury yields…
Rising UK government bond yields have pushed up borrowing costs and sharpened the focus on where future productivity gains might come from. Artificial intelligence in healthcare offers one clear answer. It aims to cut waste, speed up diagn…
The Trump administration has selected 10 companies, including AbbVie (ABBV [https://seekingalpha.com/symbol/ABBV]), Amgen (AMGN [https://seekingalpha.com/symbol/AMGN]), Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), and GSK (GSK [http…
Biotech companies are strange businesses to think about in terms of competitive advantages. A software company can lock customers into an ecosystem for years. A manufacturer can have a cost advantage. A biotech company, meanwhile, can spen…
In late September and early October 2026, AstraZeneca PLC, Daiichi Sankyo and Summit Therapeutics announced a series of clinical collaboration agreements to test ivonescimab in combination with Datroway (datopotamab deruxtecan) and sonesit…
Healthcare stocks were little changed late Friday afternoon with the NYSE Healthcare Index and the S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), the oncology and biopharmaceutical company, expanded its cancer-drug collaboration with Summit Therapeutics as U.S. shares edge a bit lower at $157.10 at 11.35am ET on Octob…
Sanofi SNY and Regeneron Pharmaceuticals REGN announced that they have expanded their existing longstanding antibody collaboration to include four next-generation, long-acting antibodies targeting type II inflammation. More on the Latest S…
Johnson & Johnson JNJ markets a broad portfolio of blockbuster medicines through its Innovative Medicine segment, with treatments across areas including neuroscience, cardiovascular and metabolic diseases, immunology, oncology, pulmonary h…
Summit Therapeutics (SMMT) is back in focus after AstraZeneca agreed to invest about US$2 billion through convertible preferred stock and entered a non exclusive clinical collaboration built around ivonescimab combinations. Summit Therapeu…
[The answers lie in the evidence] PixelsEffect/iStock via Getty Images * Daiichi Sankyo (DSKYF [https://seekingalpha.com/symbol/DSKYF]) and AstraZeneca entered into a clinical trial collaboration agreement with Summit Therapeutics (SMMT [h…
TOKYO, October 02, 2026--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. (Nasdaq: SMMT) to evaluate Datroway® (datopot…
Collaboration Intends to Evaluate Ivonescimab in Combination with Datroway across Multiple Tumor Types Starting with a Phase III Study in First-Line Triple Negative Breast Cancer MIAMI, October 02, 2026--(BUSINESS WIRE)--Summit Therapeutic…
AstraZeneca PLC (NASDAQ:AZN) said on September 28 that it will make a $2 billion equity investment in Summit Therapeutics, Inc. (NASDAQ:SMMT) and run joint trials of the two companies' cancer drugs. The money buys preferred shares converti…